Impact of Hyperkalemia and Worsening Renal Function on the Use of Renin Angiotensin Aldosterone System Inhibitors in Chronic Heart Failure With Reduced Ejection Fraction-Reference-Cited by-同舟云学术

Impact of Hyperkalemia and Worsening Renal Function on the Use of Renin Angiotensin Aldosterone System Inhibitors in Chronic Heart Failure With Reduced Ejection Fraction

Published:2017-07-14 Issue:3 Volume:102 Page:389-391
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Pitt B¹,Rossignol P²

Affiliation:

1. University of Michigan School of Medicine; Ann Arbor Michigan USA

2. Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, Inserm U1116, CHRU, Nancy; Université de Lorraine, and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists); Nancy France

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference10 articles.

1. The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure;Pitt;Expert Opin. Drug Saf.,2016

2. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study;Juurlink;N. Engl. J. Med.,2004

3. Spironolactone use and renal toxicity: population based longitudinal analysis;Wei;BMJ,2010

4. The frequency of hyperkalemia and its significance in chronic kidney disease;Einhorn;Arch. Intern. Med.,2009

5. Utilization pattern of mineralocorticoid receptor antagonists in contemporary patients hospitalized with acute decompensated heart failure: a single-center experience;Chamsi-Pasha;J. Card. Fail.,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence;European Journal of Heart Failure;2022-08-02

2. The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up;Frontiers in Medicine;2022-03-11

3. Effect of sacubitril valsartan on cardiac function and endothelial function in patients with chronic heart failure with reduced ejection fraction;Clinical Hemorheology and Microcirculation;2021-05-06

4. Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction;European Journal of Heart Failure;2020-01-09

5. A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology;European Heart Journal Supplements;2019-02-01